NOX provides update to Nyrada Note Holders  
    NOX Appendix 4D Half-year report  
    NOX Appendix 4C – December 2018 Quarter  
    December 18 Nyrada Update  
    NOXOPHARM 2018 Annual General Meeting Presentations  
    NOX releases latest corporate presentation  
    Appendix 4C – September 2018 Quarter  
    Noxopharm Releases Report on Key Progress of Subsidiary Nyrada  
    Annual Report to shareholders  
    Noxopharm Subsidiary Nyrada Announces Important Drug Discovery  
    Appendix 4E - Preliminary final report  
    AFR 30 August 2018 : Advances in Biotech - Lower cholesterol treatment breakthrough  
    Nyrada- key progress with cholesterol-lowering drug candidate  
    Appendix 4C – June 2018 Quarter  
    Nyrada, Inc. Newsletter 2. April 2018  
    Half Year Financial Statement- 31 December 2017  
    Appendix 4D - Half-Year Report  
    Noxopharm Closes $4M Capital Raising for its US Subsidiary, Nyrada,Inc.  
    Nyrada,Inc. Newsletter 1. Jan/Feb 2018  
    Nyrada Inc. Information Memorandum Convertible Notes  
    NOX Open Briefing Corporate Presentation  
    Nyrada Inc. Opens Capital Raise Memorandum Released  
    Identification of NYX-104, a promising lead candidate for the treatment of stroke and other excitotoxicity- associated disorders.  
    NYX-104 delivers Key Proof of Concept in Stroke Animal Model  
    NOX AGM Corporate Presentation  
    Completion of Transfer of Sharesto Nyrada Inc.  
    Results of General Meeting (“EGM”) of Members – 6 November 2017  
    EGM presentations  
    NOX/UNSW collaboration confirms drug designed to help stroke victims  
    Appendix 4C - Quarterly report for the quarter ended September 30, 2017  
    US biotech to develop Australian science  
    Annual Report to shareholders  
    October 19th Open Briefing Corporate Presentation  
    Establishment of Nyrada Inc. - Extraordinary General Meeting  
    Establishment of Nyrada Inc.  
    Noxopharm and UNSW combine on stroke project  
  Subscribe to Email Alerts